SuperworthBioventus profit margin BVS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- 9.4%
- Operating margin, 12 months
- 10.0%
- Net margin on a year earlier
- +9.5 pts
- Peer median
- 6.5%
Over the twelve months to Jun 27, 2026, Bioventus kept 9.4% of its revenue as net profit, with an operating margin of 10.0% and a gross margin of 68.7%.
Five years earlier its net margin was 8.5%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 4.0% | 9.5% | 68.3% |
| FY2024 | −6.3% | −2.7% | 67.7% |
| FY2023 | −30.5% | −16.0% | 64.1% |
| FY2022 | −31.0% | −32.7% | 64.6% |
| FY2021 | 4.5% | 2.8% | 70.3% |
| FY2020 | 5.1% | 6.6% | 72.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 9.4% | +9.5 pts | 10.0% | |
| Q1 FY26 | 4.9% | +10.9 pts | 10.0% | |
| Q4 FY25 | 4.0% | +10.3 pts | 9.5% | |
| Q3 FY25 | 1.3% | +8.9 pts | 7.5% | |
| Q2 FY25 | −0.1% | +8.1 pts | 6.1% | |
| Q1 FY25 | −6.0% | −1.8 pts | −2.7% | |
| Q4 FY24 | −6.3% | +24.2 pts | −2.7% | |
| Q3 FY24 | −7.5% | +28.7 pts | −3.9% | |
| Q2 FY24 | −8.2% | +47.2 pts | −4.3% | |
| Q1 FY24 | −4.2% | +51.6 pts | 2.9% | |
| Q4 FY23 | −30.5% | +0.5 pts | −16.0% | |
| Q3 FY23 | −36.2% | −11.6 pts | −19.6% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Bioventus' size, closest first, today.
| Company | Profit margin |
|---|---|
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| STAAStaar Surgical | 1.1% |
| IRMDIradimed | 26.7% |
| EYENational Vision | 2.5% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| MOVMovado | 6.0% |
| UFPTUFP Technologies | 11.4% |
| MDXGMimedx | 1.8% |
| TCMDTactile Systems Technology | 7.1% |
| Peer median | 6.5% |
Where Bioventus ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Bioventus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.